QQQ   265.19 (-1.89%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.14 (+2.71%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
QQQ   265.19 (-1.89%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.14 (+2.71%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
QQQ   265.19 (-1.89%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.14 (+2.71%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
QQQ   265.19 (-1.89%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.14 (+2.71%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:EDITEditas Medicine Stock Price, Forecast & News

$34.19
-1.32 (-3.72 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.98
Now: $34.19
$35.96
50-Day Range
$28.92
MA: $31.59
$36.84
52-Week Range
$14.01
Now: $34.19
$39.96
Volume792,000 shs
Average Volume1.00 million shs
Market Capitalization$1.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.99
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Editas Medicine logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.53 million
Book Value$5.12 per share

Profitability

Net Income$-133,750,000.00
Net Margins-404.88%

Miscellaneous

Employees133
Market Cap$1.89 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$34.19
-1.32 (-3.72 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

How has Editas Medicine's stock been impacted by Coronavirus?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EDIT shares have increased by 68.7% and is now trading at $34.19.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Editas Medicine?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Editas Medicine
.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Editas Medicine
.

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) released its earnings results on Thursday, August, 6th. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.37. The company earned $10.75 million during the quarter, compared to the consensus estimate of $6.34 million. Editas Medicine had a negative return on equity of 56.01% and a negative net margin of 404.88%. The firm's quarterly revenue was up 361.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.69) earnings per share.
View Editas Medicine's earnings history
.

What price target have analysts set for EDIT?

7 brokers have issued 12 month target prices for Editas Medicine's shares. Their forecasts range from $28.00 to $65.00. On average, they expect Editas Medicine's share price to reach $45.00 in the next year. This suggests a possible upside of 31.6% from the stock's current price.
View analysts' price targets for Editas Medicine
.

Has Editas Medicine been receiving favorable news coverage?

News headlines about EDIT stock have been trending negative recently, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Editas Medicine earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Editas Medicine
.

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), QUALCOMM (QCOM), Shopify (SHOP) and Intel (INTC).

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • Dr. Charles Albright, Chief Scientific Officer (Age 61)
  • Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.05%), Viking Global Investors LP (0.75%), Bank of New York Mellon Corp (0.57%), Swiss National Bank (0.25%), California Public Employees Retirement System (0.22%) and Russell Investments Group Ltd. (0.21%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer.
View institutional ownership trends for Editas Medicine
.

Which institutional investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Viking Global Investors LP, First Trust Advisors LP, Creative Planning, WINTON GROUP Ltd, US Bancorp DE, PNC Financial Services Group Inc., and Westside Investment Management Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, and Cynthia Collins.
View insider buying and selling activity for Editas Medicine
.

Which institutional investors are buying Editas Medicine stock?

EDIT stock was purchased by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, Swiss National Bank, Virtu Financial LLC, Rafferty Asset Management LLC, Principal Financial Group Inc., and Aigen Investment Management LP.
View insider buying and selling activity for Editas Medicine
.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $34.19.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.89 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.